Author's posts
Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
Regeneron Pharmaceuticals, one of the largest biotechnology companies, and gene therapy upstart Bluebird Bio will team up to invent genetically modified white blood cells that can attack cancer.
Regeneron’s Billionaire Founder Battles The Drug Pricing System
Regeneron’s Leonard Schleifer condemns greed at other drug firms. But what about the $37,000 price tag on his eczema drug?
23andMe Gets $300 Million Boost From GlaxoSmithKline To Develop New Drugs
GlaxoSmithKline, a London-based drug giant is partnering with 23andMe, the San Francisco genetics startup, to develop new medicines. The companies will split costs and profits equally, and Glaxo will make a $300 million investment in 23andMe. The colla…
Glaxo’s New Research Chief Loves Big Pharma. Now He Has To Fix It
GlaxoSmithCline is turning to a new chief scientific officer, Hal Barron, to reinvigorate its drug pipeline.
Biotech Entrepreneur, 29, Raises $32 Million To Use AI To Develop Drugs For Parkinson’s, ALS
Alice Zhang was a graduate student at UCLA when she decided that there was a tremendous opportunity to speed up the process of drug development. “We could start taking the guesswork out of drug discovery.”
Trump Phones, And Pfizer Reverses Price Hikes. But Why?
Pfizer, one of the world’s largest drug companies, reversed price hikes it had taken on dozens of medicines last week after a phone call between the company’s chief executive, President Donald Trump, and the Secretary of Health and Human Services, Alex…
Theranos? Whatever. Healthcare Startups Have Raised $15 Billion So Far This Year
The total number of companies splitting that cash pile has dropped, from 855 in the first six months of 2017 to 779 in the first half of 2018, meaning investors have chosen to make bigger bets in a smaller number of companies.
Vivek Ramaswamy’s Enzyvant Asks FDA To Approve Treatment For Dying Babies
“At the end of the day the metric of our success as a business is going to be the number and quality of new medicines that we get approved by the FDA and regulators in other markets,” Ramaswamy said in an interview. “Everything else is just the means t…
Biogen And Eisai Say Alzheimer’s Drug A Success, Reversing Earlier Result
A complicated new clinical trial could give some hope to Alzheimer’s patients and investors in drug companies. But there are lots of devilish details.
For Healthcare Incumbents, Naming Atul Gawande To Lead Health Nonprofit Is A Relief
It’s not that Gawande is not the perfect person for the job, but that choosing him gives the clearest indication yet of what the job will actually be
